This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
| INTRODUC TI ON
Immunoglobulin G4-related disease (IgG4-RD) is a newly defined chronic fibro-inflammatory disorder characterized by elevated serum IgG4 levels, tumefactive lesions with a dense lymphoplasmacytic infiltration rich in IgG4 positive plasma cells and storiform fibrosis of related organs. [1] [2] [3] Glucocorticoids are the first-line agents for the treatment of IgG4-RD; [4] [5] [6] [7] however, in order to maintain long-term disease stability and avoid disease relapse, usually glucocorticoids maintenance therapy should last for a long period, which may induce various glucocorticoid-associated adverse reactions. For some IgG4-RD patients with mild symptoms, such as swelling of the lacrimal glands, submandibular glands, parotid glands and nasal sinus, without internal organ damage, long-term glucocorticoids therapy for mild symptoms may have a low benefit/risk ratio. Further, a substantial proportion of patients cannot tolerate glucocorticoids.
Iguratimod (T-614) is a new small molecule compound with anti-inflammation and immune regulation functions which have a definite disease-modifying effect in both animal rheumatoid arthritis (RA) models and patients. [8] [9] [10] [11] In vitro studies had demonstrated that iguratimod has an anti-inflammatory role by inhibiting tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, IL-8, and monocyte chemotactic protein-1 production. 10 Furthermore, iguratimod could reduce the levels of serum IgG, IgM, and IgA in RA patients. 9, 10 Iguratimod could also attenuate proteinuria and kidney injury in MRL/lpr lupus mice, and improve serum markers such as anti-double-stranded DNA (anti-dsDNA) and serum C3. 12 In order to investigate an optimum treatment regime for mild IgG4-RD patients, we launched an investigator-initiated study; after treatment with one dose of diprospan, patients were given iguratimod 25 mg, twice a day, orally. The aim of this study was to evaluate the therapeutic efficacy and safety of iguratimod plus corticosteroid as bridge therapy in the treatment of IgG4-RD with mild symptoms.
| ME THODS

| Study design
This study was conducted in Peking Union Medical College Hospital (PUMCH) between 2017 and 2018. The protocol was approved by the Ethics Committee of PUMCH (No. JS-1404). The study was conducted in compliance with the Declaration of Helsinki and is registered at http://clini caltr ials.gov (NCT03368274). All enrolled patients and healthy controls consented to attend this study and provided signed written informed consent.
Newly diagnosed IgG4-RD patients, with mild but progressive superficial glands swelling were enrolled in this study, and were treated with 1 dose of diprospan, 1 mL (containing 5 mg betamethasone dipropionate and 2 mg betamethasone sodium phosphate), and concomitantly took iguratimod 25 mg, twice a day, orally. Patients were evaluated at baseline, 12 and 24 weeks of follow-up. Blood and urine routine tests, erythrocyte sedimentation rate (ESR), highsensitivity C-reactive protein (hsCRP), serum immunoglobulin, IgG subclass and IgE were measured; organ involvement was evaluated by ultrasound scanning, computed tomography (CT), or magnetic resonance imaging, or positron emission tomography/CT (PET/CT).
The treatment efficacy was evaluated by IgG4-RD responder index (IgG4-RD RI, 2012 version, each affected organ was individually scored) 13 and physician global assessment (PGA, scored as 0-10 cm).
T cell subpopulations, B cell subpopulations plasma cells, as well as serum cytokines, including IL-1β, IL-17A, TNF-α, transforming growth factor (TGF)-β1, interferon (IFN)-γ were measured at baseline and at 3 months by flow cytometry and cytometric beads array (CBA). In addition, patients' serum metabolomics before and 3 months after treatment were analyzed.
Peripheral blood from healthy donors was collected for comparison of cytokines and T cell subpopulations. plasmablast/plasma cells and memory B cells. The LC-MS based plasma metabolomic profiles revealed significant changes between untreated patients and healthy donors, which became much similar to normal states after treatment. Iguratimod plus corticosteroid as bridge therapy is effective for the treatment of mild IgG4-RD, it can improve the clinical symptoms, reduce serum IgG and IgG4 levels, especially plasmablasts/plasma cells and memory B cells. In addition, the metabolite profiling became similar to normal controls after treatment. Thirty untreated patients fulfilled the inclusion criteria and without exclusion criteria were enrolled in this clinical trial.
| Inclusion and exclusion criteria
Conclusion:
| Primary and secondary outcomes
The primary outcome of this study was to evaluate the response rate 
| Efficacy assessment
Treatment response was assessed by evaluating the changes of IgG4-RD RI scores and was divided into three types: complete response (CR), partial response (PR) and no effect (NE, including no improvement or exacerbation). IgG4-RD RI scores <3 and declining ≥2 were recognized as a CR; IgG4-RD RI scores declining ≥2 but remaining ≥3 were recognized as a PR. If a patient's IgG4-RD RI score was 3 points at the beginning, PR was considered as a 1 point decrease after the therapy. Patients with lack of apparent changes in mass sizes and/or clinical manifestations and IgG4-RD RI scores declining <2 were considered to be NE. 4, 15 The relapse of IgG4-RD included two types, clinical relapse and serological relapse. 4 Clinical relapse was defined as recurrence or aggravation of clinical symptoms or imaging findings with or without IgG4 concentrations elevation. Serological relapse was defined as clinical symptoms remained stable while serum IgG4 level increased more than 1 score in IgG4-RD RI.
| Safety assessment
Safety was assessed using adverse events reports, physical examinations, and laboratory tests including hematology, liver and kidney function. These safety assessments were undertaken at screening and at all the follow-up periods.
| CBA, enzyme-linked immunosorbent assay (ELISA), and flowcytometry
Cytometric beads array kits of human IL-1β, IL17A, TNF-α, TGF-β and IFN-γ were from BD Biosciences. Human B cell activating factor (BAFF) ELISA kit was from Rockland, USA.
Peripheral blood mononuclear cells from IgG4-RD patients and healthy controls were separated by Ficoll gradient centrifugation.
Antibodies and staining for cell subsets are shown in Data S1. T cells were defined as CD3+ T cells, CD3+ CD4+ T cells, CD3+ CD8+ T cells, CD4+ CXCR5+ TFH (T follicular helper) cells, CD4+ CXCR5+ PD-1+ / ICOS+ TFH cells, CD4+ IFN-γ+ Th1 cells, CD4+ IL17A+IFNγ± Th17 cells. B cell subsets were defined as CD19+ CD24-CD38hi plasmablast/ plasma cells, CD19+ CD27hiCD38hi plasmablasts, CD19+ IgD-CD38hi plasmablasts, CD19+ IgD+CD38± naïve B cells, CD19+ IgD-CD38-CD27+ memory B cells. Plasma cells were defined as CD38+ CD138+. shown in Data S1. 
| Metabolomics analysis
| Statistical analysis
| RE SULTS
| Patients' clinical characteristics and demographics
| Demographics of IgG4-RD patients
In total, 30 untreated IgG4-RD patients were enrolled in this study. The age was 50.8 ± 10.2 years with disease duration of 31.5 (interquartile range 8-66) months. The male/female ratio was 1:1.
Eighteen (60%) patients had a history of allergy. The percentage of allergic rhinitis, asthma, drug allergy, dust mite allergy and eczema were 33.3%, 13.3%, 6.6%, 3.3% and 3.3%, respectively.
Twenty-five (83.3%) patients finished this study. Four patients withdrew because of no response or exacerbation, one patient with good response stopped iguratimod treatment at 3 months because of economic reasons.
| Clinical characteristics of IgG4-RD
The percentages of affected organs, including lacrimal glands, submandibular glands, lymph nodes, parotid glands and nasal/paranasal sinus, were 76.7%, 53.3%, 36.7%, 10% and 53.3%, respectively.
All patients had slow but active disease progression, and needed to be treated; none of them had internal organs involvement. 
| Treatment efficacy
| Primary endpoint
| Secondary endpoint
Changes of laboratory examinations
Baseline hemoglobin (HGB), white blood cells, lymphocytes and percentage of eosinophil were 138.8 ± 17.2 g/L, 6.57 ± 1.85 × 10 9 /L, 2.11 ± 0.69 × 10 9 /L and 2.4% (Q1-Q3, 1.65%-4.25%), respectively. Figure 1 ).
| Safety assessment
Of all 30 patients enrolled, no severe adverse reactions were found in this study. During follow-up, 6 (20%) patients had mild side effects, including three with oral ulcers, two with stomach discomfort, and one with mild hair loss. No patients showed abnormality in blood routine tests, liver function or renal function. Of patients with stomach discomfort, omeprazole and life-style changes helped alleviate this discomfort (Table S1 ). Oral ulcers and hair loss were alleviated to some extent by applying vitamin B and reducing the dosage of iguratimod to once a day.
| Cytokine levels before and after treatment
Plasma cytokines were tested at baseline and 3 months after treatment. After treatment, IFN-γ decreased from 0.868 ± 0.374 pg/mL to 0.396 ± 0.331 pg/mL, P = 0.025. BAFF was 792.87 ± 98.44 pg/mL, and decreased to 696.64 ± 86.88 pg/mL after treatment, P = 0.027.
There was no significant changes in serum TGF-β1, IL-1β, IL-17A and TNF-α before and after treatment.
| Changes of T and B cell subsets before and after treatment
T cell and B cell subsets were measured before and 3 months after treatment by flow cytometry (Figures S1 and S2 ). Of T cell subsets, CD3+ T cells were 56.49% ± 16.28% in lymphocytes, which decreased significantly to 41.88% ± 15.4% after 3 months treatment, P = 0.003 ( Figure 2 ). CD3 + CD8 + T cells also decreased from 22.61% ± 10.94% to 16.13% ± 8.02%, P = 0.03 ( Figure 2 ). There was no statistical significance of CD3+ CD4+ T cells, CD4+ CXCR5+ TFH ( Figure 2 ), or the expression of PD-1 and ICOS on CD4+ CXCR5+
TFH cells before and after treatment. And there was no statistical significance in Th17 cells among healthy controls and IgG4-RD patients before and after treatment.
Of B cell subsets, there was no significance of total CD19+ B cells before (4.52% ± 2.47%) and after (5.11% ± 3.45%) treatment.
Plasmablast/plasma cells, expressed as CD19 + CD24-CD38hi, decreased from 7.21% ± 7.51% to 3.83% ± 4.68% after 3 months treatment, P = 0.007 (Figure 3 ). CD19 + CD27hiCD38hi plasmablasts also significantly decreased from 7.75% ± 6.87% to 4.07% ± 4.65%, P = 0.007. CD19 + IgD-CD38hi plasmablasts decreased from 6.98% ± 6.26% to 3.69% ± 4.16%, P = 0.003. Naïve B cells defined as CD19+
IgD+CD38± were increased from 57.23% ± 12.81% to 69.13% ± 9.48%, P = 0.001 (Figure 3 ). In addition, there was a reduction of CD19+ IgD-CD38-CD27+ memory B cells from 10.98% ± 5.36% to 8.14% ± 3.4% after treatment, P = 0.049.
| Metabolomics analysis
| Global metabolic profiling
In order to characterize the difference in metabolic profiling between the healthy control group (Group A), IgG4-RD initial group (Group B) and iguratimod treatment IgG4-RD group (Group C), OPLS-DA (orthogonal partial least squares-discriminant analysis) and PLS-DA (partial least squares-discriminant analysis) were performed.
As shown in Figure S3 , a clear separation of Group A and Group B was achieved. To estimate the efficacy of iguratimod treatment, PLS-DA statistical analysis was conducted among the three groups ( Figure 4A,B) . The PLS-DA ESI+ data showed cumulative values of R2(Y) = 55% and Q2 = 43% and PLS-DA ESI-showed R2(Y) = 42%
and Q2 = 28%. The results indicated excellent clustering and clear distinction. Group C was located between Groups A and B, but overlapped with Group A in both ionization mode. Distance between samples were measured and clustered by dendrogram clustering; a similar changing trend was observed in the dendrogram clustering results ( Figure S4) . The results suggested that iguratimod treatment affected systematic metabolic profiles, which restored the metabolic pattern back or near normal levels.
| Biomarker identification and metabolic pathway reconstruction
A total of 229 metabolites were significantly changed between Group A and Group B, including 88 in positive ion mode and 141 in negative ion mode. These candidates include amino acid metabolites, carboxylic acids compounds and lipid compounds.
To further explore the metabolic pathways involved in IgG4-RD, the identified metabolites were subjected to software IMPaLA (Table   S2 ). As shown in Figure 4C , there were multiple metabolic pathways (P < 0.05) constructed with the corresponding metabolites, including glycerophospholipid metabolism, sphingolipid metabolism and choline metabolism. We found phosphatidylcholines (PCs), lyso-phospatidylcholines (lyso-PCs), phosphatidylethanolamine, sphingomyelins (SMs) and glycocholic acid were involved in most of these pathways.
It suggested that these compounds were significantly associated with IgG4-RD and might be potential indicators of IgG4-RD (Table   S3 ). Thus, heatmap analysis was performed to assess the variation in the three groups ( Figure 4D ). Compared with healthy controls, biomarkers were significantly changed in initial IgG4-RD patients. After iguratimod treatment, most of these metabolites were reversed to near normal. The result revealed that iguratimod treatment could ameliorate the abnormal state of metabolism induced by IgG4-RD.
| D ISCUSS I ON
In this study, iguratimod with corticosteroid as bridge treatment for Iguratimod is a member of the methane sulfonanilide family; although most of the members of this family act as cyclo-oxygenase 2 (COX 2) inhibitors, iguratimod was considered as a novel immunomodulator based on more and more evidence. Further, iguratimod was also recommended as a disease-modifying anti-rheumatic drug by Japan, the Asia-Pacific League of Associations for Rheumatology
Congress and the Chinese guidelines on the treatment of RA.
Existing studies revealed that iguratimod reduced the production of cytokines including IFN-1β, IL-6, IL-8 and IL-17A both in vitro and in vivo. 20 Further, iguratimod could reduce immunoglobulin production in both mice and humans with RA. 21 Iguratimod could also attenuate proteinuria and kidney injury in MRL/lpr lupus mice, and improve serum markers such as anti-dsDNA and serum C3. 12 In addition, there are some studies published in Chinese which showed igura- This is the first study evaluating therapeutic effects and mechanisms of iguratimod on IgG4-RD through biochemistry and metabolomics. In the present study, we have demonstrated the LC-MS-based metabolic profile of initial IgG-RD patients from iguratimod-treated patients and healthy controls. Between IgG4-RD patients and healthy controls, metabolites with statistical significance were mainly involved in glycerophospholipid metabolism, choline metabolism and phospholipid metabolism pathway. Phospholipids were found to be a potential panel of IgG4-RD. Iguratimod treatment could provide significant effects on IgG4-RD through restoring multiple pathways and related biomarkers to normal levels, similar to patients treated with glucocorticoids combined with/without immunosuppressants (data not shown). Therefore, iguratimod is a promising drug in the application of IgG4-RD treatment.
This study had some limitations. First, this was a one-arm study without a control group. As there was no "golden" or "anchor" immunosuppressant drug for treatment of IgG4-RD, we did not set controls for this trial. Second, all patients were given one dose of diprospan; we should take into consideration that diprospan might affect the evaluation of iguratimod. Third, patients and doctors were not blinded which may have contributed to some biases.
In conclusion, iguratimod plus corticosteroid as bridge therapy is effective for the treatment of mild IgG4-RD; it can improve the clinical symptoms of patients, reduce the serum IgG and IgG4 levels, and can also reduce the peripheral CD3+ CD8+ T cells, and especially plasmablasts and memory B cells. Iguratimod is well tolerated in IgG4-RD patients. Clinical trial registration number: NCT03368274.
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